Puma Biotechnology has been notified by the U.S. Food and Drug Administration FDA that its Investigational New Drug Application IND submission has been reviewed, and Puma can proceed with the
Puma Biotechnology has been notified by the U.S. Food and Drug Administration FDA that its Investigational New Drug Application IND submission has been reviewed, and Puma can proceed with the
In a regulatory filing, Puma Biotechnology (PBYI) noted that on September 22, 2021, the company and Wyeth, as co-plaintiffs, filed suit against AstraZeneca (AZN) for infringement of United States Patent
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Puma Biotechnology (PBYI – Research Report). The associated price target is $7.00. Edward White has given his Buy
H. C. Wainwright הורידו את מחיר היעד שלהם עבור Puma Biotechnology ל-7 דולר מה-8 דולר הקודם אך עדיין ממליצים על רכישת המניה. הם התאימו את תחזיתם לביצועי החברה בשנת 2025
H.C. Wainwright lowered the firm’s price target on Puma Biotechnology to $7 from $8 and keeps a Buy rating on the shares, citing a lower 2025 non-GAAP EPS estimate of